SI · Insider Trading
Shoulder Innovations, Inc.
Every open-market purchase and sale reported by SI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Paul Buckman | Director | A | +1,275 | +$24.99K |
| 2026-10-06 | Kevin K. Sidow | Director | A | +892 | +$17.48K |
| 2026-10-06 | Andrew Hykes | Director | A | +669 | +$13.11K |
| 2026-10-06 | Casey M Tansey | Director | A | +733 | +$14.37K |
| 2026-09-14 | Robert Joseph Ball | CEO & Executive Chairman | MIXED | +79,058 | −$424 |
| 2026-08-28 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −1,196 | −$27.03K |
| 2026-08-24 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −25,097 | −$567.41K |
| 2026-08-18 | Matthew Fraser Ahearn | Chief Operating Officer | MIXED | −25,000 | −$464.81K |
| 2026-08-07 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −9,433 | −$213.48K |
| 2026-08-07 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −9,433 | −$213.48K |
| 2026-08-05 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −110,563 | −$2.52M |
| 2026-08-03 | Gilde Healthcare Holding B.V. | 10%+ Owner | Sell | −48,279 | −$1.12M |
| 2026-06-29 | Richard Buchholz | Director | A | +5,046 | — |
| 2026-06-29 | Andrew Hykes | Director | A | +5,046 | — |
| 2026-06-29 | Paul Buckman | Director | A | +5,046 | — |
| 2026-06-29 | Casey M Tansey | Director | A | +5,046 | — |
| 2026-06-29 | Kevin K. Sidow | Director | A | +5,046 | — |
| 2026-06-16 | Matthew Fraser Ahearn | Chief Operating Officer | Sell | −20,000 | −$374.25K |
| 2026-04-21 | Matthew Fraser Ahearn | Chief Operating Officer | M | +21,664 | +$59.17K |
| 2026-03-17 | Richard Buchholz | Director | Buy | +1,000 | +$14.84K |
| 2026-03-17 | Robert Joseph Ball | CEO & Executive Chairman | Buy | +2,200 | +$33.39K |
| 2026-03-17 | Jeffrey S. Points | Chief Financial Officer | MIXED | +15,264 | +$62.90K |
| 2026-03-17 | Paul Buckman | Director | MIXED | +38,600 | −$49 |
| 2026-02-10 | Robert Joseph Ball | CEO & Executive Chairman | M | +12,062 | +$29.13K |
| 2026-02-03 | Jeffrey S. Points | Chief Financial Officer | A | +126,357 deriv. | — |
| 2026-02-03 | Matthew Fraser Ahearn | Chief Operating Officer | A | +88,450 deriv. | — |
| 2026-02-03 | Robert Joseph Ball | CEO & Executive Chairman | A | +265,351 deriv. | — |
| 2026-02-03 | David Lawrence Blue | See Remarks | A | +88,450 deriv. | — |
| 2026-01-08 | David Lawrence Blue | See Remarks | A | +1,041 | +$12.66K |
| 2026-01-08 | Matthew Fraser Ahearn | Chief Operating Officer | A | +477 | +$5.80K |
| 2026-01-08 | Robert Joseph Ball | CEO & Executive Chairman | A | +1,661 | +$20.20K |
| 2026-01-08 | Jeffrey S. Points | Chief Financial Officer | A | +1,076 | +$13.08K |
| 2025-12-15 | Jeffrey S. Points | Chief Financial Officer | Buy | +2,000 | +$29.63K |
| 2025-12-15 | Robert Joseph Ball | CEO & Executive Chairman | Buy | +7,200 | +$107.01K |
| 2025-09-15 | Robert Joseph Ball | CEO & EXECUTIVE CHAIRMAN | Buy | +8,000 | +$122.75K |
| 2025-09-15 | David Lawrence Blue | SEE REMARKS | M | +94,394 | +$204.14K |
| 2025-09-15 | Jeffrey S. Points | CHIEF FINANCIAL OFFICER | MIXED | +14,864 | +$57.97K |
| 2025-09-15 | Matthew Fraser Ahearn | CHIEF OPERATING OFFICER | M | +107,345 | +$217.27K |
| 2025-08-05 | Geoffrey B Pardo | Director | MIXED | +2,388,148 | +$1.50M |
| 2025-08-05 | Paul Buckman | Director | MIXED | +13,864 | — |
| 2025-08-05 | Gilde Healthcare Holding B.V. | 10%+ Owner | MIXED | +2,380,482 | +$1.50M |
| 2025-08-05 | Robert Joseph Ball | CEO & EXECUTIVE CHAIRMAN | C | +85,888 | — |
| 2025-08-05 | Jeffrey S. Points | CHIEF FINANCIAL OFFICER | Buy | +50 | +$750 |
| 2025-08-05 | Kevin K. Sidow | Director | MIXED | +20,010 | — |
| 2025-08-05 | David Lawrence Blue | SEE REMARKS | C | +43,937 | — |
| 2025-08-05 | Michael A Carusi | Director | MIXED | +1,892,802 | +$4.00M |
| 2025-08-05 | Casey M Tansey | Director | MIXED | +2,740,787 | +$600.00K |
| 2025-08-05 | Matthew Fraser Ahearn | CHIEF OPERATING OFFICER | C | +67,242 | — |
| 2025-08-05 | Lightstone Ventures II, L.P. | — | MIXED | +9,425,680 | +$20.00M |
| 2025-08-05 | Richard Buchholz | Director | MIXED | +12,666 | +$75.00K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Geoffrey B Pardo | Director | 2,388,148 | $47.46M |
| Gilde Healthcare Holding B.V. | 10%+ Owner | 2,185,914 | $43.45M |
| Michael A Carusi | Director | 1,892,802 | $37.62M |
| Lightstone Ventures II, L.P. | — | 1,885,136 | $37.47M |
| Robert Joseph Ball | CEO & Executive Chairman | 380,824 | $7.57M |
| Matthew Fraser Ahearn | Chief Operating Officer | 266,676 | $5.30M |
| David Lawrence Blue | See Remarks | 139,372 | $2.77M |
| Casey M Tansey | Director | 139,031 | $2.76M |
| Jeffrey S. Points | Chief Financial Officer | 68,835 | $1.37M |
| Paul Buckman | Director | 65,025 | $1.29M |
| Kevin K. Sidow | Director | 25,948 | $515.72K |
| Richard Buchholz | Director | 18,712 | $371.90K |
| Andrew Hykes | Director | 7,438 | $147.83K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.